255 related articles for article (PubMed ID: 33932114)
1. Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Yokomizo A; Koga H; Ito K; Takezawa Y; Komiyama M; Nishimura K; Yonese J; Hashine K; Masumori N; Arai G; Saito S; Shinohara M; Shimizu N; Yamauchi A; Satoh T; Tochigi T; Kobayashi M; Fujimoto H; Kakimoto KI; Fukui I; Tsukamoto T; Nozaki M; Karasawa K; Hasumi M; Ohtani M; Ishiyama H; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Naito S; Yamanaka H;
Cancer Med; 2021 May; 10(10):3240-3248. PubMed ID: 33932114
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
3. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
4. [Risks of diabetes mellitus and impaired glucose tolerance induced by intermittent versus continuous androgen-deprivation therapy for advanced prostate cancer].
Zeng S; Li ZP; Li W; Pu WZ; Liu P; Ma ZF
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):598-602. PubMed ID: 29723451
[TBL] [Abstract][Full Text] [Related]
5. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
6. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
7. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
8. Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.
Dason S; Allard CB; Wang JG; Hoogenes J; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):28-36. PubMed ID: 24775721
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.
Tsai HT; Penson DF; Makambi KH; Lynch JH; Van Den Eeden SK; Potosky AL
Urology; 2013 Aug; 82(2):327-33. PubMed ID: 23896094
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.
Roy S; Grimes S; Morgan SC; Eapen L; Malone J; Craig J; Spratt DE; Malone S
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1101-1113. PubMed ID: 33524545
[TBL] [Abstract][Full Text] [Related]
11. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
Sargos P; Mottet N; Bellera C; Richaud P
BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
[TBL] [Abstract][Full Text] [Related]
12. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
15. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.
Casas F; Henríquez I; Bejar A; Maldonado X; Alvarez A; González-Sansegundo C; Boladeras A; Ferrer F; Hervás A; Herruzo I; Caro M; Rodriguez I; Ferrer C
Clin Transl Oncol; 2017 Mar; 19(3):373-378. PubMed ID: 27770397
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T
Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
18. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
[TBL] [Abstract][Full Text] [Related]
19. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff JM; Abrahamsson PA; Irani J; da Silva FC
BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer.
Roy S; Grimes S; Eapen L; Spratt DE; Malone J; Craig J; Morgan SC; Malone S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1179-1188. PubMed ID: 32565318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
